FATE News and Press, Fate Therapeutics Inc. From 03/07/23

San Diego, California--(Newsfile Corp. - March 7, 2023) - The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Fate Therapeutics, Inc. (NASDAQ: FATE). Investors who purchased Fate Therapeutics, Inc. (NASDAQ: FATE) shares prior to April 2, 2020,...

Fate Therapeutics, Inc. (FATE) Q4 2022 Earnings Conference Call February 28, 2023 17:00 ET Company Participants Scott Wolchko - President and Chief Executive Officer Wayne Chu - Chief Medical Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research ...

Fate Therapeutics press release ( NASDAQ: FATE ): Q4 GAAP EPS of -$0.58 beats by $0.29 . Revenue of $44.34M (+159.8% Y/Y) beats by $25.93M . Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents, and Receivables For further details see: Fate Th...

Ended 2022 with Approximately $475 Million in Cash, Cash Equivalents, and Receivables Multi-dose Treatment Cohorts Initiated in FT576 Phase 1 Study for Multiple Myeloma; Interim Clinical Data from Single-dose Cohorts Showed Objective Responses and Selective Depletion of Activated Host I...

SAN DIEGO, CA / ACCESSWIRE / February 28, 2023 / The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in NASDAQ:FATE shares. However, investors who purchased Fate Therapeutics, Inc. (NASDAQ:FATE) shares prior to April 2, 2020, and continue to hold any of t...

Fate Therapeutics ( NASDAQ: FATE ) is scheduled to announce Q4 earnings results on Tuesday, February 28th, after market close. The consensus EPS Estimate is -$0.85 and the consensus Revenue Estimate is $18.41M (+7.9% Y/Y). Over the last 3 months, EPS estimates have seen 6 up...

New York, New York--(Newsfile Corp. - February 13, 2023) - Levi & Korsinsky, LLP notifies investors in Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ: FATE) of a class action securities lawsuit. The lawsuit on behalf of Fate investors has been commenced in the the United States ...

SAN DIEGO, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived c...

SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Fate Therapeutics, Inc. (NASDAQ: FATE). Investors who purchased Fate Therapeutics, Inc. (NASDAQ: FATE) shares prior to April 2, 2020, and conti...

BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engage...